Biophan-die neue Microsoft?!
Seite 43 von 113 Neuester Beitrag: 26.07.23 00:01 | ||||
| Eröffnet am: | 15.05.04 09:58 | von: aida73 | Anzahl Beiträge: | 3.824 |
| Neuester Beitrag: | 26.07.23 00:01 | von: MrTrillion3 | Leser gesamt: | 360.964 |
| Forum: | Hot-Stocks | Leser heute: | 44 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 40 | 41 | 42 | | 44 | 45 | 46 | ... 113 > | ||||
_________________________________
Space Act Agreement Focused on Development of Advanced Thermoelectric Materials for Implantable Power Systems
Moffett Field, CA and Rochester, NY, August 17, 2004. Biophan Technologies, Inc. (OTCBB: BIPH), announced today that its TE-Bio subsidiary has signed an agreement with NASA for characterization and joint development of high-density, nanoengineered thermoelectric materials for use with implantable medical devices. Research will be conducted at the NASA Ames Research Center for Nanotechnology in Moffett Field, CA.
Successful outcomes of the agreement are anticipated to provide breakthrough power generation systems for use in implanted medical devices, such as pacemakers, as well as long-life, light-weight power for use in future space exploration applications. Specifically, NASA is supporting Biophan's efforts and hoping to utilize its technology to further develop on-board power for astronaut health monitors.
The Nanotechnology Center at NASA Ames will provide access to expertise in a collaborative arrangement for the benefit of both parties. The agreement combines NASA's expertise with thermoelectric materials and state-of-the-art nanotechnology development with Biophan's innovative power solution that has the potential to greatly improve patient quality of life and lower healthcare costs.
"This agreement with NASA highlights our commitment to collaborate with world-class development centers for commercializing the technologies that are part of Biophan's portfolio," stated Michael Weiner, CEO of Biophan. "Crew health and safety is a key concern in the U.S. space programs and we expect this relationship to be mutually beneficial. With each new agreement, the viability of our research and that of our subsidiaries grows, and we look forward to a long, fruitful development alliance with NASA."
"We are pleased to be working with Biophan on a joint research initiative to help advance the concept of an implanted biothermal power source to power medical sensing and therapeutic devices. On deep space missions such as a trip to Mars, having efficient ways to monitor and treat astronauts can be very useful, the benefits for humans with implanted devices is very clear," said David Lackner, technology partnership manager at NASA Ames Research Center.
Biophan recently acquired a majority interest in TE-Bio, the research and development company that is developing the long-life power source serving as the subject of the agreement with NASA.
About the NASA Ames Center for Nanotechnology
NASA Ames’ nanotechnology effort started in early 1996 and has steadily grown to establish a Center for Nanotechnology. The research work focuses on experimental research and development in nano and biotechnologies as well as on a strong complementary modeling and simulation effort that includes computational nanotechnology, computational nanoelectronics, computational optoelectronics, and computational modeling of processes encountered in nanofabrication. The Center has about 55 scientists working on the above aspects; in addition, graduate students, faculty on sabbatical or summer visits, and undergraduate and high school students work at the Center through various internship programs.
The Center's vision is to develop novel concepts in nanotechnology for NASA's future needs on electronics, computing, sensors, and advanced miniaturization of all systems; and to develop highly integrated and intelligent simulation environment that facilitates the rapid development and validation of future generation electronic devices as well as associated materials and processes through virtual prototyping at multiple levels of fidelity. For more information, please visit www.ipt.arc.nasa.gov.
Man, komm mal runter, oder wieso biste so aggressiv? Hab ich das gesagt? *kopfschüttel*
From government research to private industry, cash is starting to flow into nanotechnology, much of it through cooperative research centers funded by industry, government and institutional investors.
The Defense Advanced Research Projects Agency (DARPA) awarded $10.3 million to Nanosolar Inc. to continue its development of solar electricity cells. The news was released late Tuesday.
Biophan Technologies, Inc. announced today that its TE-Bio subsidiary has signed an agreement with NASA for joint development of high-density, nanoengineered thermoelectric materials for use with implantable medical devices.
" This agreement with NASA highlights our commitment to collaborate with world-class development centers for commercializing the technologies that are part of Biophan's portfolio," stated Michael Weiner, CEO of Biophan.
Biophan's NASA announcement fell on the heels of Weiner's having spoken at a Financial Investment Analysts Money Managers Society (FAMMS) meeting in New York last week. FAMMS, an industry association of New York City-based investment professionals, were given an over view of the company's technology and business strategy by Weiner. At the meeting, Weiner discussed Biophan's latest patents and biomedical technologies and fielded questions from the analysts and money managers.
According to a report by Lux Research, world spending on nanotechnology research will top $8.6 billion this year. The U.S. has now appropriated more than $3.16 billion to fund nanotechnology R&D since 2000 and is proposing $982 million in new funding for FY 2005. The US government will spend nearly twice as much on nanotechnology this year as it did on the Human Genome Project (HGP) in its peak year. In 2005, the National Nanotechnology Initiative will surpass the HGP on a cumulative basis.
Lux Research's report, " The Nanotech Report 2004," says corporations will spend more than $3.8 billion globally on nanotechnology R&D in 2004 alone.
In Kolkata India Tuesday, speakers at a nanotechnology meeting of government, industry, educational and research organizations, criticized industry for not investing more heavily in nanotechnology research.
Experts from the nanotechnology sector urged Indian industry to invest substantially in the sector for industrial applications in the areas of electronics and computers, pharma and biomedical sector.
Speakers were of the opinion that in India, investment in nanotechnology was very low compared to countries like the US, where more than 500 corporations were investing in this field of research.
Nanotechnology fever seems to be sweeping the globe with events like these happening daily and more investors are beginning to get the bug, and thanks to research organizations like Lux, they're able to get a better picture of just how big this new industry is.
Most of the nanotech sector stocks are relatively unheard of, like Biophan (BIPH), Isonics (ISON) or Perfisans (PFNH). All companies making breakthrough developments in the nanotechnology sector and who've all been saying what Lux Research apparently validated, that the nanotechnology market was going to explode with growth
... daher das stärkere Plus als in Amiland.
1052. obige News ist übrigens vom 17.8.... optiman 18.08.04 17:45
# 1047. "pushen? Hab ich davor auch gepusht oder was? o. T."
Man, komm mal runter, oder wieso biste so aggressiv? Hab ich das gesagt? *kopfschüttel*
Wie soll ich das verstehen? hast du es gesagt oder nicht?
Biophan Announces Investor Conference Call at 12:00 pm Eastern Today
ROCHESTER, N.Y.
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Michael Weiner, 585-214-2441
President and CEO to Discuss Joint Development Agreement with NASA's Ames Research Center for Nanotechnology
Biophan Technologies, Inc. (OTCBB: BIPH), a leading developer of next generation biomedical technology, announced today that it will host an investor conference call today at 12:00 pm Eastern to discuss its agreement with NASA for characterization and joint development of high-density, nano-engineered thermoelectric materials for use with implantable medical devices. Research will be conducted at the NASA Ames Research Center for Nanotechnology, Moffett Field, CA.
The Company will discuss the impact and market opportunities represented by this joint development agreement on the conference call. Following the discussion, Michael Weiner, president and CEO of Biophan, will be available to answer questions regarding the technologies that may emerge from the partnership with the NASA Ames Research Center. Participants may ask questions during the Q & A segment of the call or, if they prefer, may e-mail questions in advance of the call to Michael Briola, executive vice president of Trilogy Capital Partners, michael@trilogy-capital.com.
To access the call, Investors should call 800-553-0351, or from an international location 612-332-0820, and request the "Biophan Conference Call." The discussion will also be webcast via streaming audio; to listen on the web, simply go to the Trilogy Capital Partners home page, at www.trilogy-capital.com, and click on the banner link for the conference call.
NASA hopes to use Biophan's innovative biothermal power solution to develop new on-board power for astronaut health monitors.
Biophan is developing new power systems for implantable medical devices using body heat to generate power. These are intended to replace or augment traditional power systems, such as lithium iodine batteries. By using the body's generation of heat as a power source, significantly longer life power systems are possible.
"The agreement with NASA highlights our commitment to collaborate with world-class development centers for commercializing the technologies that are part of Biophan's portfolio," stated Weiner. "With each new agreement, the viability of our research and that of our subsidiaries grows."
"We are pleased to be working with Biophan on a joint research initiative to help advance the concept of an implanted biothermal power source to power medical sensing and therapeutic devices," said David Lackner, technology partnership manager at NASA Ames Research Center. "On deep space missions, such as a trip to Mars, it's critical to have the efficient methods to monitor and treat astronauts."
Biophan recently acquired a majority interest in TE-Bio, developer of a patented innovation in thermoelectric materials using nanoscale-based, thin-film materials to convert body heat into electrical energy. The resulting power can be used to "trickle charge" batteries for medium-power devices such as defibrillators, or to directly power low-energy devices, such as pacemakers. These power systems have the potential to run for as long as 30 years-a five-fold increase in service life over existing technology-and thus may reduce the number of replacement implant medical procedures needed throughout a patient's life, reducing costs and potential complications.
News Announcement: Video
To view the online joint announcement from the NASA Ames Development Center at Moffett Field California, go to www.trilogy-capital.com.
About the NASA Ames Center for Nanotechnology
NASA Ames' nanotechnology effort started in early 1996 and has steadily grown to establish a Center for Nanotechnology. The research work focuses on experimental research and development in nano and biotechnologies as well as on a strong complementary modeling and simulation effort that includes computational nanotechnology, computational nanoelectronics, computational optoelectronics, and computational modeling of processes encountered in nanofabrication. The Center has about 55 scientists working on the above aspects; in addition, graduate students, faculty on sabbatical or summer visits, and undergraduate and high school students work at the Center through various internship programs.
The Center's vision is to develop novel concepts in nanotechnology for NASA's future needs on electronics, computing, sensors, and advanced miniaturization of all systems; and to develop highly integrated and intelligent simulation environment that facilitates the rapid development and validation of future generation electronic devices as well as associated materials and processes through virtual prototyping at multiple levels of fidelity. For more information, please visit www.ipt.arc.nasa.gov.
About Biophan Technologies
Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 16 issued U.S. patents and 60 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.
About TE-Bio
TE-Bio holds an exclusive license to a patented innovation for generating power for an implantable medical device using thermoelectric materials. The technology is applicable to a wide variety of devices from biosensors to cardiodefibrillators. TE-Bio is a limited liability company owned 51% by Biophan Technologies, Inc., and 49% by Biomed Solutions, LLC. The company is developing the thermoelectric materials and related circuits, and will provide these devices to biomedical device manufacturers and battery companies on an OEM basis.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Copyright © 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
News Copyright © 2004 Interest!ALERT All rights reserved.
wurde sogar übertroffen.grins.ich denke du kannst hier ruhigen gewissens weiter posten.bin seit gestern zu 0,62 und heute nochmals zu 0,80 dabei.wie siehst du die morgige veranstaltung? Das Ende der Fahnenstange ist lange nicht erreicht.Es ist noch nicht offiziell in den USA mit der News.Die kam erst gegen 16,01 amerikanischer Zeit.Ich denke wir starten um 15,30 bei ca 1$ und dann den Tag verfolgen....
du schreibst ja schon ziemlich lange hier und hast vielleicht die ein oder andere quelle?nur mutmaßung,aber wer eine verdopplung vorhersagt in ne absolute abwärtsbewegung...... IOCircuit.com Announces China Wireless Increases Revenues by 542%
LAKE HARMONY, PA - MARKET WIRE - 08/19/04
China Wireless Communications, Inc. (OTC BB: CWLC) announces that revenues for the month of July 2004 increased 542% to $67,955 vs. $10,576 for the comparable period of April 2004. The comparison of 1st month Q2 vs. 1st month Q3 demonstrates the acceptance of the Company's products and services by its Chinese customer base. China Wireless is pleased with these results and continues to actively market its suite of products on its Beijing fiber network. These products include fiber, wireless, international high speed broadband transport, data hosting, VDSL (Very High Speed Digital Subscriber Line) ISP (Internet Service Provider) transport connections and enterprise integration services.
About China Wireless Communications, Inc.
China Wireless Communications, Inc., headquartered in Denver, CO provides a suite of broadband data services, including support for Internet access and Voice over IP in Beijing, China through its wholly owned subsidiary, In-Touch Communications. We use secure, reliable fixed wireless technology to provide the 'last mile' connection to link bandwidth-hungry businesses to our fiber- optic backbone, and to the networks of our telecommunications partners. Our "Wireless Fiber" services provide the capacity and reliability of fiber-optic networks, over a fixed wireless connection. As a result, we capitalize on faster deployment and maintain targeted capital spending available only through these advanced technologies. Our systems are used to provide redundant high-speed network access connections, Voice over IP and transport services that include IP data, video and ISP services. The Company is publicly traded on the OTCBB under the symbol "CWLC."
Other active stocks are Biophan Technologies Inc. (OTC: BIPH), Skyway Communications Holdings Corp. (OTC: SWYC), Qiao Xing Universal Telephone Inc. (OTC: XING).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. IOCircuit.com accepts no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has paid IOCircuit.com $625.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. IOCircuit.com has no ownership of equity and no representation of accuracy in the above company and our reports are designed to communicate company announcements through our Press Release Service.
Optionen
| Boardmail an "Börsenfan" |
Wertpapier: Biophan Technologies |
viertel bis halbe stunde vor börsenbeginn richtig hoch getaxt werden,genau wie gestern.gestern war er bis kurz vor eröffnung noch ziemlich niedrig, um dann innerhalb von ein paar minuten 15% höher getaxt zu werden.denke über 0,9$ wird die eröffnung auf jeden fall liegen. Optionen
| Boardmail an "Börsenfan" |
Wertpapier: Biophan Technologies |
rein zu kommen (so wie ich zu 0,80).klar übertrieben, aber vielleicht hat aida recht und wir eröffnen um die 1$ Marke.da kann es ziemlich schnell rauf gehen.habe auch noch ne order tiefer drin stehen. ;O) Es kann auch schon wahrleich so sein,dass wir über der 1$ Marke schliessen und bei ca ,90 eröffnen.
Ich denke auch,dass sich einige Amerikaner heut schon in Germany eingekauft haben.
Bin gespannt wie es ab 15,30 Uhr läuft und was die Konferenz bringt.unsere amerikanische Freunde in den Boards sind schon ganz aufgeregt,was heut läuft
Optionen
| Boardmail an "Börsenfan" |
Wertpapier: Biophan Technologies |